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Background
Chemotherapy and vaccination with tumor-loaded dendri-
tic cells (DCs) show poor impact on overall survival (OS)
in metastatic melanoma1,2. Ipilimumab (IPI) improves OS
throughout the blockade of CTLA4-mediated inhibitory
signals in T-cells and restores the efficiency of the anti-
genic cross-priming by mature (m) DCs3. However, varia-
tion of immune cells to evaluate the response to IPI does
not reflect the T-cell activation and is a modest predictor
of clinical response. Recent studies in human and experi-
mental melanoma demonstrated that mDCs release endo-
mysial microvescicles namely dexosomes (Dex) showing a
functional anti-melanoma activity as well as an antigenic
profile resembling that of circulating mDCs including
CD40, CD80 and CD86 co-stimulatory molecules.
This research is aimed to identify an early biomarker of
T-cell activation for predicting the clinical response in IPI-
treated melanoma patients.
Methods
Thirthy-four patients with metastatic melanoma were
treated with IPI and sera collected at each infusion. Serum
Dex were purified by the ‘Total Exosome Isolation kit’
(Invitrogen) and conjugated with magnetic beads of 4 μm
of diameter (Dynabeads). Dex were first identified by size
and then CD40, CD80 and CD86 expression was evaluated
by flow-cytometry using relative MoAbs. The response to
IPI was analyzed up to 12 weeks after the end of treat-
ment, according to RECIST criteria. Moreover, DEX levels
were compared with clinical and immunological para-
meters by the Mann-Withnet test.
Results
Both CD40 and CD80 expression was unchanged after
the end of IPI treatment with respect to basal levels,
whereas a significant increase of Dex-CD86 expression
occurred as compared to baseline (21.3±1.5% vs
12.0±0.8%, p<0.05) in 5 patients with partial response
and 1 in complete remission (19.4±1.2% vs. 9.9±1.1%). A
weak trend to the increment of Dex-CD86 occurred in
patients with stable disease, while those in clinical pro-
gression showed low levels in all instances. CD86
expression was apparently unrelated to LDH levels and
absolute leukocyte count.
Conclusions
Level of CD86 expressed by Dex reflects the immunolo-
gical activation in melanoma patients treated with IPI.
Therefore, the measurement of soluble Dex-CD86 could
be an early marker of response to IPI and predict the
efficiency of immunological response.
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